GOLDMAN SACHS GROUP INC (GS) Stock News

Rosen Law Firm has filed securities class action lawsuits against Photronics, Inc., First Solar, Inc., and Intuit Inc., alleging that defendants made materially false and misleading statements to investors. In the Photronics case, the firm claims the company concealed a critical bottleneck in its design release pipeline and falsely promised seasonal recovery following Chinese New Year. Investors who purchased securities during the specified class periods are encouraged to seek counsel before the lead plaintiff deadline of September 4, 2026.

A securities class action lawsuit has been filed against GeneDx Holdings Corp. for alleged misrepresentations regarding the Fabric acquisition's impact on the company's business. Investors who purchased GeneDx common stock between April 16, 2025 and May 4, 2026 may be entitled to compensation. The lead plaintiff deadline is August 3, 2026.

Rosen Law Firm is reminding Lucid Group, Inc. investors who purchased securities between February 25, 2026 and April 13, 2026 of the July 28, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Lucid made false and misleading statements regarding supplier quality issues that disrupted Lucid Gravity deliveries and negatively impacted the company's business and financial results.

Rosen Law Firm is reminding investors in Sportradar Group AG (NASDAQ: SRAD) who purchased shares between November 7, 2024 and April 21, 2026 of the July 17, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Sportradar made false statements about its compliance practices and intentionally worked with black-market gambling operators while claiming strict regulatory compliance.

Vanguard's VGSH and VanEck's SMB are compared as short-term bond ETF options. VGSH offers lower costs (0.03% expense ratio), higher yields (3.85%), and larger assets ($33.9B), making it attractive for general investors. SMB provides tax-exempt municipal bond income (2.76% yield) suited for high-bracket taxpayers, though with slightly higher expenses (0.07%) and lower liquidity ($312.7M). Both funds minimize interest rate risk through short durations, with VGSH having ~2 years maturity versus SMB's 3+ years.

GeneDx Holdings Corp. (WGS) faces a securities class action lawsuit over alleged misleading statements regarding its Fabric Genomics acquisition. The company announced a $51 million acquisition in April 2025, but by May 2026 disclosed a $31.2 million impairment charge, a $65 million revenue guidance cut, and a 49.20% single-day stock collapse. The lead plaintiff deadline is August 3, 2026.

GeneDx Holdings Corp. (NASDAQ: WGS) faces a class action lawsuit alleging that executives made false statements about the viability of its Fabric Genomics acquisition. The company revealed significant problems on May 4, 2026, including a drop in adjusted gross margin from 74% to 69%, reduced earnings projections, and a $31.3 million impairment loss, causing the stock to plummet over 49%. Investors with substantial losses have until August 3, 2026 to seek appointment as lead plaintiff.

A class action lawsuit has been filed against Citadel Securities LLC and Virtu Americas LLC for allegedly engaging in 'spoofing' - a manipulative trading practice involving submitting and cancelling orders without intent to execute them - to artificially influence Genius Group Limited (GNS) stock prices and increase transaction costs for investors. The lead plaintiff deadline is August 28, 2026.

Rosen Law Firm is encouraging investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026 to join a securities class action lawsuit. The lawsuit alleges that GeneDx made false statements regarding the Fabric acquisition's positive impact on the company's financials and operations, when in reality the company knew of significant viability problems that would negatively impact the business. The lead plaintiff deadline is August 3, 2026.

Faruqi & Faruqi, LLP is investigating a federal securities class action against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making false and misleading statements about its Fabric Genomics acquisition and overstating the durability of reimbursement rates. On May 4, 2026, GeneDx disclosed missed Q1 results, cut 2026 guidance from $540-555M to $475-490M, and took a $31.3M goodwill impairment charge on the $36.5M Fabric Genomics acquisition. The stock fell 49% ($33.42 per share) on the news. The deadline to seek lead plaintiff appointment is August 3, 2026.

A securities class action lawsuit has been filed against GeneDx Holdings Corp. for allegedly making false statements about the Fabric acquisition's impact on the company's financials and operations. Investors who purchased GeneDx stock between April 16, 2025 and May 4, 2026 may be entitled to compensation. The lead plaintiff deadline is August 3, 2026.

Vanguard offers two short-term bond ETFs with identical 0.03% expense ratios but different risk profiles. VGSH focuses exclusively on U.S. Treasury securities for maximum safety with lower volatility, while BSV includes investment-grade corporate bonds and international debt for higher yields but greater drawdown risk. The choice depends on investor risk tolerance and desired credit exposure.

Bernstein Liebhard LLP has announced multiple securities class action lawsuits against Megan Holdings Limited (MGN), Photronics, Inc. (PLAB), and GRAIL, Inc. (GRAL). The lawsuits allege that defendants made materially false and misleading statements regarding their businesses and operations, causing securities to trade at artificially inflated prices. Investors who suffered losses during the respective class periods are encouraged to contact the firm.

Hagens Berman is investigating a securities class action lawsuit against GeneDx Holdings (WGS) alleging executives misled investors about the Fabric Genomics acquisition and its synergy potential. The company's stock collapsed 49% on May 5, 2026, following a disastrous Q1 2026 earnings report that included a $31.2 million impairment charge on the Fabric Genomics unit, representing 94% of the acquisition cost. GeneDx also reported a tenfold increase in net loss, missed revenue targets, and slashed 2026 guidance by 12%.

Gray Media, Inc. announced it will release its Q2 2026 earnings results on August 7, 2026, followed by a conference call at 11:00 a.m. ET. The company is the nation's largest owner of local television stations, serving 117 markets reaching approximately 37% of US television households.

Rosen Law Firm is reminding investors who purchased Verra Mobility Corporation stock between February 24, 2026 and May 26, 2026 of an important August 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Verra provided false and misleading statements regarding its relationship with Avis Budget Group and contract extension prospects, while concealing material adverse facts. Investors may be entitled to compensation through a contingency fee arrangement.

Rosen Law Firm is notifying investors who purchased Badger Meter common stock between April 18, 2024 and April 16, 2026 about a securities class action lawsuit. The lawsuit alleges that Badger Meter made materially false and misleading statements about its financial results and growth prospects by concealing that strong results were partially driven by pulling forward customer orders to recognize revenue early, which masked weakening demand. The lead plaintiff deadline is August 3, 2026.

A securities class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making false statements regarding the Fabric acquisition's impact on the company's financials and operational efficiencies. Investors who purchased GeneDx common stock between April 16, 2025 and May 4, 2026 may be entitled to compensation. The deadline to serve as lead plaintiff is August 3, 2026.

Robbins Geller Rudman & Dowd LLP announced a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making false statements regarding the Fabric Genomics acquisition. GeneDx revealed significant problems with the acquisition on May 4, 2026, including a drop in adjusted gross margin from 74% to 69%, reduced earnings projections, and a $31.3 million impairment loss, causing the stock to plummet over 49%. Investors with substantial losses can seek appointment as lead plaintiff by August 3, 2026.

A federal securities class action has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging that the company and its executives made false and misleading statements about the Fabric Genomics acquisition and overstated the durability of reimbursement rates. On May 4, 2026, GeneDx disclosed missed Q1 results, cut 2026 guidance from $540-555 million to $475-490 million, and took a $31.3 million goodwill impairment charge on the Fabric Genomics acquisition purchased for $36.5 million one year prior. The stock fell over 49% on the news. Investors who purchased GeneDx stock between April 16, 2025 and May 4, 2026 may be eligible to participate in the lawsuit, with a deadline of August 3, 2026 to seek lead plaintiff appointment.

Hagens Berman is investigating a securities class action lawsuit against GeneDx Holdings (WGS) alleging executives misled investors about the Fabric Genomics acquisition and its synergy potential. The company's stock collapsed 49% on May 5, 2026, following a disastrous Q1 2026 earnings report that included a $31.2 million impairment charge on the Fabric Genomics unit, representing 94% of the acquisition cost. GeneDx also reported a tenfold increase in net loss, missed revenue targets, and slashed 2026 guidance by 12%.

A securities fraud class action lawsuit has been filed against GeneDx Holdings Corp. for allegedly making material misstatements about the viability of its $51 million acquisition of Fabric Genomics. The company wrote off a $31.3 million impairment loss on the Fabric acquisition in Q1 2026, causing the stock to plunge 49%. Investors who purchased WGS stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to seek lead plaintiff status.

A securities class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) for alleged misrepresentations regarding the Fabric acquisition's impact on the company's business. Investors who purchased GeneDx common stock between April 16, 2025 and May 4, 2026 may be entitled to compensation. The lead plaintiff deadline is August 3, 2026.

Rosen Law Firm is reminding investors in GRAIL, Inc. (NASDAQ: GRAL) who purchased stock between May 13, 2025 and February 19, 2026 of an August 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that GRAIL provided misleading statements about its NHS-Galleri trial results, concealing material adverse facts about the trial's ability to demonstrate cancer reduction outcomes. Investors may be eligible for compensation through a contingency fee arrangement.

Hagens Berman is investigating a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) alleging executives misled investors about the Fabric Genomics acquisition and its synergy potential. The company's stock collapsed 49% on May 5, 2026, following a disastrous Q1 2026 earnings report that included a $31.2 million impairment charge on the Fabric Genomics unit, representing 94% of the acquisition cost. GeneDx also reported a tenfold increase in net loss, missed revenue targets, and slashed 2026 guidance by 12%.

Pomerantz LLP has filed a class action lawsuit against GeneDx Holdings Corp. alleging securities fraud and unlawful business practices. The lawsuit stems from GeneDx's May 4, 2026 announcement of disappointing Q1 2026 results, including a drop in adjusted gross margin from 74% to 69%, reduced earnings guidance from $540-$555M to $475-$490M, and a $31.3M impairment loss related to its April 2025 acquisition of Fabric Genomics. GeneDx's stock fell 49.20% on the news. Investors have until August 3, 2026 to request Lead Plaintiff status.

GSI Technology announced its participation in the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, in Boston. CEO Lee-Lean Shu and VP Didier Lasserre will present the company's Associative Processing Unit (APU) technology and provide updates on proof-of-concept programs and early-stage deployments in defense, smart infrastructure, and intelligent surveillance markets.

A securities fraud class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making material misstatements about the viability of its $51 million acquisition of Fabric Genomics. The company wrote off a $31.3 million impairment loss on the Fabric acquisition in Q1 2026, causing WGS stock to plummet over 49%. Investors who purchased WGS stock between April 16, 2025, and May 4, 2026, can seek lead plaintiff status by August 3, 2026.

Rosen Law Firm is reminding investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026 of the August 3, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GeneDx made false statements regarding the Fabric acquisition's positive impact on the company's financials and operations, when in reality the company knew of significant viability problems that would negatively impact the business.

Rosen Law Firm has filed securities class action lawsuits against Graphic Packaging Holding Company, Zoetis Inc., and Embecta Corp. The lawsuit against Graphic Packaging alleges the company made false statements regarding inventory management, demand, costs, and financial guidance during the Class Period of February 4, 2025 to February 2, 2026. Investors with losses exceeding $100,000 are encouraged to join the class action before the July 6, 2026 deadline.